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2352-3964/© 2014 The Author. Published by Elsevier B.VAsthma affects over 300 million people worldwide and its preva- tance of different potential therapeutic targets. With several new thera-
lence continues to rise. It is typically characterised by intermittent
symptoms of breathlessness, cough and wheeze punctuated with asth-
ma attacks together with variable airﬂow obstruction, which are more
frequent and persistent in severe disease (Chung et al., 2014). Under-
pinning this clinical presentation is airway inﬂammation and remodel-
ling (Hartley et al., 2014).
Airway inﬂammation in asthma is typically eosinophilic in associa-
tionwith allergic sensitisation, particularly in thosewith early onset dis-
ease (Chung et al., 2014; Hartley et al., 2014). Allergen challenge is an
established asthmamodelwith features of both an early, predominately
mast cell mediated, and a late asthmatic response driven by a more
complex inﬂammatory response characterised by eosinophilic inﬂam-
mation. However, beyond allergic asthma there is an increasing
recognition that the inﬂammatory response in asthma is more hetero-
geneous with both eosinophilic and neutrophilic inﬂammation mediat-
ed by a combination of Th1/Tc1, Th2 and Th17 cytokines. Importantly,
these inﬂammatory proﬁles do not necessarily occur independently,
but may co-exist to varying degrees within an individual over time.
The aetiology of neutrophilic asthma is poorly understood and is likely
in part due to effects of high dose corticosteroid therapy, exposure to
pollutants and pathogens (Hartley et al., 2014). Although the cause of
eosinophilic and neutrophilic inﬂammatory responses in an individual
are not fully understood granulocyte trafﬁcking has been studied exten-
sively and the critical growth factors, cytokines, chemokines and adhe-
sion molecules have been described that coordinate hematopoiesis,
bonemarrow egression, adhesion to the endothelium, selective chemo-
taxis and survival in tissue (Hartley et al., 2014).
Our understanding of granulocyte trafﬁcking has underpinned the
development of several biologic and small molecule therapies targeting
granulocyte recruitment and survival in asthma including anti-IL5, anti-
CRTh2, anti-CCR3, and anti-CXCR2 (Chung et al., 2014; Hartley et al.,
2014; Nair et al., 2012; Haldar et al., 2009; Ortega et al., 2014). It is
therefore perhaps somewhat surprising that our knowledge of the dy-
namics of granulocyte trafﬁcking in humans in both health and disease
remains limited and that this lack of understanding not only impacts
upon a more comprehensive insight into mechanisms of granulocyte
migration, but also challenges our understanding of the relative impor-om.2014.10.014.
icester LE3 9QP, UK.
. This is an open access article underpies in late phase development this greater insight would help to better
position these therapies and inform the development of others. There-
fore safe and reliable systems to track granulocytes in asthma are
required.
To address this challenge Lukawska and colleagues report in this
issue of EBioMedicine a small proof-of-concept study of real time, differ-
ential tracking of human eosinophil and neutrophil migration in 12
atopic asthmatics following allergen challenge (Lukawska et al., 2014).
This is an extension of their earlier work reported with healthy volun-
teers (Lukawska et al., 2014) and is similar to reports by others explor-
ing granulocyte trafﬁcking in health (Farahi et al., 2012, 2014). They
puriﬁed eosinophil and neutrophils from the asthmatic subjects
radiolabelled them, re-infused the cells and tracked the granulocyte ki-
netics by scintigraphy. They found that neutrophil efﬂux in the lungs
was slower than eosinophils and systemic corticosteroid reduced lung
retention of eosinophils albeit non-signiﬁcantly. The study was small
and underpowered to observe important clinical changes following al-
lergen challenge to associate with the granulocyte trafﬁcking, but does
provide conﬁdence for further clinical development. The study focused
upon allergen challenge, but to understand granulocyte dynamics
other established models would be valuable to explore such as viral or
lipopolysaccharide challenges. The approach described by Lukawska
and colleagues also increased activation of eosinophils and neutrophils
which limits exploration of trafﬁcking in health whereby the cells are
unlikely to be activated (Farahi et al., 2012), but whether this is a
major limitation in disease needs to be further explored.
In vivo real time tracking of granulocytes has immediate impact
upon early phase clinical development as it can be incorporated into
model systems to explore the effects of therapies upon granulocyte mi-
gration. However, with an increasing number of potential targets un-
derstanding their relative importance in different model systems and
ultimately in speciﬁc patient subgroups is critical and is the drive to-
wards stratiﬁed medicine. One approach to begin to dissect this com-
plexity is multi-scale computational modelling, which might provide
some important insights and becomekey in drug development and clin-
ical decisions (Burrowes et al., 2013). These multi-scale models can be
applied to predict relative mechanistic responses to therapies in silico.
Intervention studies can then inform, validate and further extend
these models to improve their clinical utility. This parallel approach of
in silicomodelling with in vivo experimental approaches that closely re-
ﬂect the disease will inform asthma mechanisms and improve a strati-
ﬁed approach to therapy. Therefore, understanding the dynamics ofthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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way destination continues to be an important focus of research.
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